Neurona Therapeutics

Neurona Therapeutics, founded in 2008, is a biotherapeutics company with the slogan "Building the next generation of cell-based medicines". The company is focused on developing neural cell therapies with single-dose curative potential for chronic neurological disorders. Their pioneering work in a novel neural cell lineage has enabled the development of a robust regenerative platform. Neurona is currently working on neuronal, glial, and gene-edited cell therapy candidates aimed at providing long-term repair of dysfunctional neural networks for multiple neurological disorders. The last noteworthy investment in Neurona was a substantial $120.00M Series E investment on 08 February 2024. Notably, the investors participating in this round include The Column Group, Berkeley Frontier Fund, Cormorant Asset Management, Euclidean Capital, Spur Capital Partners, UCB Ventures, Viking Global Investors, Willett Advisors, Ysios Capital, and SymBiosis. The company operates primarily in the Biotechnology and Health Care industries, with its headquarters located in the United States. Considering the significant investment and the impressive lineup of investors, Neurona Therapeutics is poised to make substantial strides in the field of neural cell therapies and has the potential to become a key player in the biotechnology landscape. For more information, one can visit Neurona's website.